title: A recombinant varicella vaccine harboring a respiratory syncytial virus gene induces humoral immunity.
abstract: The varicella-zoster virus (VZV) Oka vaccine strain (vOka) is highly efficient and causes few adverse events; therefore, it is used worldwide. We previously constructed recombinant vOka (rvOka) harboring the mumps virus gene. Immunizing guinea pigs with rvOka induced the production of neutralizing antibodies against the mumps virus and VZV. Here, we constructed recombinant vOka viruses containing either the respiratory syncytial virus (RSV) subgroup A fusion glycoprotein (RSV A-F) gene or RSV subgroup B fusion glycoprotein (RSV B-F) gene (rvOka-RSV A-F or rvOka-RSV B-F). Indirect immunofluorescence and Western blot analyses confirmed the expression of each recombinant RSV protein in virus-infected cells. Immunizing guinea pigs with rvOka-RSV A-F or rvOka-RSV B-F led to the induction of antibodies against RSV proteins. These results suggest that the current varicella vaccine genome can be used to generate custom-made vaccine vectors to develop the next generation of live vaccines.
authors.affiliation: Division of Clinical Virology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan; Kanonji Institute, Seto Center, The Research Foundation for Microbial Diseases of Osaka University, 4-1-70, Seto-cho, Kanonji 768-0065, Kagawa, Japan.
authors.forename: Kouki
authors.initials: K
authors.lastname: Murakami
authors.affiliation: Kanonji Institute, Seto Center, The Research Foundation for Microbial Diseases of Osaka University, 4-1-70, Seto-cho, Kanonji 768-0065, Kagawa, Japan.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Matsuura
authors.affiliation: Division of Clinical Virology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
authors.forename: Megumi
authors.initials: M
authors.lastname: Ota
authors.affiliation: Kanonji Institute, Seto Center, The Research Foundation for Microbial Diseases of Osaka University, 4-1-70, Seto-cho, Kanonji 768-0065, Kagawa, Japan.
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Gomi
authors.affiliation: The Research Foundation for Microbial Diseases of Osaka University, 3-1, Yamada-oka, Suita 565-0871, Osaka, Japan.
authors.forename: Koichi
authors.initials: K
authors.lastname: Yamanishi
authors.affiliation: Division of Clinical Virology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. Electronic address: ymori@med.kobe-u.ac.jp.
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Mori
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000096:biosynthesis / Q000276:immunology; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000276:immunology; D002644:Chickenpox / Q000276:immunology; D019433:Chickenpox Vaccine / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D016679:Genome, Viral; D006168:Guinea Pigs; D014645:Herpesvirus 3, Human / Q000276:immunology*; D056724:Immunity, Humoral; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D022261:Respiratory Syncytial Virus Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D012136:Respiratory Syncytial Viruses / Q000235:genetics* / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014760:Viral Fusion Proteins / Q000276:immunology
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D019433:Chickenpox Vaccine; D022261:Respiratory Syncytial Virus Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014760:Viral Fusion Proteins
keywords: Next generation vaccine; RSV; VZV; Vaccine